Skip to main content

Table 1 Patient information

From: Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer

Age (years)

66 (60–72)

Sex

 Female

12 (46%)

 Male

14 (54%)

Histology

 Adenocarcinoma

26 (100%)

Tumor location

 Head

21 (81%)

 Body

4 (15%)

 Tail

1 (4%)

Resectability status (at diagnosis)

 Borderline resectable

11 (42%)

 Locally advanced

15 (58%)

Induction chemotherapy

 FOLFRINOX

16 (62%)

 Gem/Abraxane

6 (23%)

  FOLFRINOX and Gem/Abraxane

4 (15%)

Time to progression (days)

120 (60–180)

Follow-up (days)

200 (111–289)

  1. Number quoted is the number of patients in each category for categorical variables, and median value for numerical variables, while the number in brackets signifies percentage of all patients in the category and 25th to 75th percentile range respectively. Follow-up time is quoted for patients who did not progress as time to censoring